Media coverage about Orexigen Therapeutics (NASDAQ:OREX) has trended somewhat negative on Tuesday, AlphaOne reports. AlphaOne, a service of Accern, rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Orexigen Therapeutics earned a coverage optimism score of -0.12 on AlphaOne’s scale. AlphaOne also assigned headlines about the biopharmaceutical company an impact score of 91 out of 100, indicating that recent media coverage is extremely likely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Alpha One Sentiment’s scoring:
Separately, ValuEngine downgraded Orexigen Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday. Orexigen Therapeutics (NASDAQ OREX) opened at 3.01 on Tuesday. Orexigen Therapeutics has a 1-year low of $1.65 and a 1-year high of $6.49. The company has a 50-day moving average price of $3.11 and a 200 day moving average price of $3.21. The firm’s market capitalization is $45.83 million.
Orexigen Therapeutics (NASDAQ:OREX) last issued its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($4.67) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.60) by $2.07. The business had revenue of $19.10 million during the quarter, compared to analyst estimates of $20 million. Orexigen Therapeutics had a negative net margin of 71.59% and a negative return on equity of 354.92%. The company’s revenue for the quarter was up 282.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.54) earnings per share. Analysts expect that Orexigen Therapeutics will post ($8.55) earnings per share for the current fiscal year. About Orexigen Therapeutics